Novartis (NOVN) PT Set at CHF 90 by Deutsche Bank

Deutsche Bank set a CHF 90 price target on Novartis (VTX:NOVN) in a research report report published on Monday. The brokerage currently has a neutral rating on the stock.

Several other brokerages have also recently weighed in on NOVN. JPMorgan Chase & Co. set a CHF 84 price target on shares of Novartis and gave the company a neutral rating in a research report on Wednesday, January 10th. Morgan Stanley set a CHF 92 price target on shares of Novartis and gave the company a buy rating in a research report on Friday, December 1st. Bank of America set a CHF 87 target price on shares of Novartis and gave the stock a sell rating in a research report on Wednesday, December 6th. Sanford C. Bernstein set a CHF 97 target price on shares of Novartis and gave the stock a buy rating in a research report on Thursday, October 26th. Finally, Societe Generale set a CHF 95 target price on shares of Novartis and gave the stock a buy rating in a research report on Wednesday, October 25th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of CHF 87.38.

Novartis (NOVN) opened at CHF 82.90 on Monday. The stock has a market capitalization of $215,430.00 and a PE ratio of 30.70. Novartis has a 52 week low of CHF 69.50 and a 52 week high of CHF 85.40.

ILLEGAL ACTIVITY WARNING: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3144984/novartis-novn-pt-set-at-chf-90-by-deutsche-bank.html.

Novartis Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.